Kathleen Farley: Mnkd VP Strategic Operations, TEVA VP US Op
Nov 2, 2015 20:00:25 GMT -5
afrezzamiracle, jefferson, and 6 more like this
Post by lakers on Nov 2, 2015 20:00:25 GMT -5
Kathleen Farley
VP Strategic Supply Chain Operations at Mannkind
Greater New York City AreaPharmaceuticals
Current
Mannkind, Core Strategy Solutions LLC
Previous
Teva Pharmaceuticals, Merck
Education
Fordham Gabelli School of Business
Summary
Kathleen has extensive Global Pharmaceutical and Chemical manufacturing and Supply Chain experience in both Generics ,Branded Proprietary drugs and Med devices. She is the Vice President of Strategic Operations for Mannkind Corporation responsible to oversee the strategic intent of the Supply agreement with Sanofi (Commercial partner). Additionally, she was responsible to help transition Mannkind from a development organization to Commercial Supply. She is currently the owner of Core Strategy Solutions LLC working with Clients to build and assess the strength of their Manufacturing and Supply Chain strategies using CORE principles of methodology.
Previously, she was the Vice President of US Operations at Teva Pharmaceuticals responsible for solid dose and speciality products US manufacturing facilities, as well as, Techinical Services, Engineering and Third Party suppply (contract manufacturing) supporting 18 billion doses, over 400 product families and $6 billion in sales. She had a P&L responsibility of ~$500 million and 2000 employees. She was directly responsible for product optimization efforts, FDA readiness initiatives, US network strategies and contingency and scenario planning.
Prior to this, at Merck, Kathleen was the VP Manufacturing Franchise head from 2007-2009 responsible for the Global end to end supply of Merck's top two Franchises, Diabetes and Respiratory, respresenting close to $9 billion in sales. Ms. Farley spent over 10 years in Latin America and was the VP of Manufacturing Operations. She had full profit & loss responsibility for over 1000 employees with a budget of $150 million suporting $1 billion in sales. Ms. Farley developed, implemented and executed the supply strategy for the LA region and took the region to one of the best in the company with improvements in Qulaity, Safety, Customer service and product costs.
She recieved her MBA from Fordham University and BS ChemEE/Minor Biomedical Engineering from Michigan State University.
Experience
Mannkind
VP Strategic Operations-Technical operations
Mannkind
September 2013 – Present (2 years 3 months)
VP Strategic Operations at Mannkind responsibilities included Supply Chain, External manufacturing, strategic sourcing to protect long term viability of the EtE supply chain, Operational excellence. Key relationship manager to Sanofi (Partner) as well as the Manufacturing lead to the Governance of the Joint partnership.
President/Owner
Core Strategy Solutions LLC
June 2012 – Present (3 years 6 months)
Ms Farley is the president of Core Strategy Solutions LLC, a consultancy built upon creating and developing Manufacturing and Supply Chain strategies using CORE Principles to focus on the strength and risks within the EtE value chain. Ms Farley is a Manufacturing Advisory Board member of Gilead Sciences, Business development consultant with Laurus Labs of India and a Part-time Professor teaching Supply Chain Strategies at Rutgers MBA program, ranked #3 in the US.
Teva Pharmaceuticals
VP US Operations
Teva Pharmaceuticals
November 2009 – January 2012 (2 years 3 months)
Head of US manufacturing operations, Technical services, Engineering and Third party supply for Generic and Branded solid dose and speciality products. Responsibilities include direct management of 8 manufacturing facilities which supply 8 b doses as well as external suppliers that produced an additional 8 b doses to the US supporting $6b in sales and over 400 product families. Total budget responsibility of ~$500 million and ~2000 employees.
Merck
VP Manufacturing Franchise Head
Merck
February 2007 – January 2009 (2 years)
Head of the manufacturing and supply chain area responsible for the End to End supply of Merck's top 5 products representing $8.5 billion in sales. Senior member of Merck's top two Franchise operating commitees acting as liase to the manufacturing/supply chain division to translate and implement the strategic direction of the corporation. Developed the long range strategic plans for Singulair, Fosamax and Januivia for the company.
Merck
VP Latin American Operations
Merck
January 1997 – June 2007 (10 years 6 months)
VP Latin American Operations with full P&L responsibility for manufacturing operations for supply of $1billion in sales with a budget of ~$150 million and ~1000 employees.
VP Strategic Supply Chain Operations at Mannkind
Greater New York City AreaPharmaceuticals
Current
Mannkind, Core Strategy Solutions LLC
Previous
Teva Pharmaceuticals, Merck
Education
Fordham Gabelli School of Business
Summary
Kathleen has extensive Global Pharmaceutical and Chemical manufacturing and Supply Chain experience in both Generics ,Branded Proprietary drugs and Med devices. She is the Vice President of Strategic Operations for Mannkind Corporation responsible to oversee the strategic intent of the Supply agreement with Sanofi (Commercial partner). Additionally, she was responsible to help transition Mannkind from a development organization to Commercial Supply. She is currently the owner of Core Strategy Solutions LLC working with Clients to build and assess the strength of their Manufacturing and Supply Chain strategies using CORE principles of methodology.
Previously, she was the Vice President of US Operations at Teva Pharmaceuticals responsible for solid dose and speciality products US manufacturing facilities, as well as, Techinical Services, Engineering and Third Party suppply (contract manufacturing) supporting 18 billion doses, over 400 product families and $6 billion in sales. She had a P&L responsibility of ~$500 million and 2000 employees. She was directly responsible for product optimization efforts, FDA readiness initiatives, US network strategies and contingency and scenario planning.
Prior to this, at Merck, Kathleen was the VP Manufacturing Franchise head from 2007-2009 responsible for the Global end to end supply of Merck's top two Franchises, Diabetes and Respiratory, respresenting close to $9 billion in sales. Ms. Farley spent over 10 years in Latin America and was the VP of Manufacturing Operations. She had full profit & loss responsibility for over 1000 employees with a budget of $150 million suporting $1 billion in sales. Ms. Farley developed, implemented and executed the supply strategy for the LA region and took the region to one of the best in the company with improvements in Qulaity, Safety, Customer service and product costs.
She recieved her MBA from Fordham University and BS ChemEE/Minor Biomedical Engineering from Michigan State University.
Experience
Mannkind
VP Strategic Operations-Technical operations
Mannkind
September 2013 – Present (2 years 3 months)
VP Strategic Operations at Mannkind responsibilities included Supply Chain, External manufacturing, strategic sourcing to protect long term viability of the EtE supply chain, Operational excellence. Key relationship manager to Sanofi (Partner) as well as the Manufacturing lead to the Governance of the Joint partnership.
President/Owner
Core Strategy Solutions LLC
June 2012 – Present (3 years 6 months)
Ms Farley is the president of Core Strategy Solutions LLC, a consultancy built upon creating and developing Manufacturing and Supply Chain strategies using CORE Principles to focus on the strength and risks within the EtE value chain. Ms Farley is a Manufacturing Advisory Board member of Gilead Sciences, Business development consultant with Laurus Labs of India and a Part-time Professor teaching Supply Chain Strategies at Rutgers MBA program, ranked #3 in the US.
Teva Pharmaceuticals
VP US Operations
Teva Pharmaceuticals
November 2009 – January 2012 (2 years 3 months)
Head of US manufacturing operations, Technical services, Engineering and Third party supply for Generic and Branded solid dose and speciality products. Responsibilities include direct management of 8 manufacturing facilities which supply 8 b doses as well as external suppliers that produced an additional 8 b doses to the US supporting $6b in sales and over 400 product families. Total budget responsibility of ~$500 million and ~2000 employees.
Merck
VP Manufacturing Franchise Head
Merck
February 2007 – January 2009 (2 years)
Head of the manufacturing and supply chain area responsible for the End to End supply of Merck's top 5 products representing $8.5 billion in sales. Senior member of Merck's top two Franchise operating commitees acting as liase to the manufacturing/supply chain division to translate and implement the strategic direction of the corporation. Developed the long range strategic plans for Singulair, Fosamax and Januivia for the company.
Merck
VP Latin American Operations
Merck
January 1997 – June 2007 (10 years 6 months)
VP Latin American Operations with full P&L responsibility for manufacturing operations for supply of $1billion in sales with a budget of ~$150 million and ~1000 employees.
love all these connections.... 
